Policy & Regulation
Neuropore Therapies Receives USD 500,000 Grant from The ALS Association to Explore ALS Treatments that Inhibit Neuronal Damage from Disease-Related Inflammation
19 February 2020 - - US-based biopharmaceutical company Neuropore Therapies, Inc has been awarded a USD 500,000 grant from The ALS Association to support the preclinical evaluation and development of its Toll-Like Receptor 2 antagonist NPT1220-312 for the treatment of amyotrophic lateral sclerosis, the company said.

The grant has been made through the Association's Lawrence and Isabel Barnett Drug Development Program.

Toll-like receptors are found on brain cells. Their function is to trigger inflammation that activates the immune system in response to bad players such as viruses or bacteria.

Research suggests that TLR2 over-activation plays a key role in driving chronic inflammation that leads to the degeneration of neurons in people with ALS and Parkinson's disease.

NPT1220-312 is a potential treatment to protect neurons from the damaging inflammation generated by TLR2 receptors.

Neuropore Therapies is developing novel small molecule therapeutics to treat and slow the progression of neurodegenerative disorders such as amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease.

The approach being taken by Neuropore is to target an underlying pathological process common to these disorders the accumulation of toxic oligomeric aggregates of misfolded neuronal proteins in cell membranes.

By preventing the formation and enhancing the clearance of these toxic aggregates synaptic function may be restored and neurodegenerative processes slowed.

The ALS Association is the largest private funder of ALS research in the world.

The Association funds global research collaborations, provides assistance for people with ALS and their families through its nationwide network of chapters and certified clinical care centers, and advocates for better public policies for people with ALS.

The ALS Association builds hope and enhances quality of life while urgently searching for new treatments and a cure.
Login
Username:

Password:


Related Headlines